Hoth Therapeutics (HOTH) Stock Price, News & Analysis

Company Overview

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies across dermatology, immunology, ophthalmology and infectious disease. The company’s mission is to advance innovative treatments that address unmet medical needs through targeted drug delivery systems and proprietary formulations. Hoth Therapeutics leverages its expertise in topical, transdermal, and ocular delivery platforms to enhance safety, efficacy and patient compliance.

The company’s lead asset, HT-001, is a topical formulation designed to treat plaque psoriasis and other inflammatory skin disorders. Preclinical and early-stage clinical data have demonstrated its potential to reduce disease activity with a favorable safety profile. In the ophthalmology space, Hoth is advancing HT-102, an eye drop formulation intended to minimize post-surgical inflammation following cataract procedures, and IMM-001, which targets macular edema associated with diabetic retinopathy and retinal vein occlusion.

Founded in 2018 and headquartered in New York City, Hoth Therapeutics has assembled a management team with deep experience in pharmaceutical R&D, regulatory strategy and commercial development. Under the leadership of CEO Michael Goldstein, the company has established strategic collaborations with contract research organizations and manufacturing partners to support its pipeline. Hoth’s board and scientific advisory members bring decades of biotech and pharmaceutical expertise, helping to guide clinical programs and streamline regulatory pathways.

Hoth Therapeutics conducts its research and clinical trials primarily in North America, while exploring opportunities for global partnerships to expand access to its therapies. By focusing on diseases with high unmet medical needs and leveraging its proprietary delivery technologies, the company aims to advance multiple programs through proof-of-concept studies and into pivotal trials. Hoth continues to explore licensing and collaboration agreements to accelerate the development and commercialization of its pipeline assets.

Key Stats

• Today's Range: $1.40 to $1.57
• 50-Day Range: $0.84 to $1.53
• 52-Week Range: $0.58 to $3.80
• Volume: 645,740 shs
• Average Volume: 3.73 million shs
• Market Capitalization: $19.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Hoth Therapeutics Stock Analysis - MarketRank™

Hoth Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 492nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Hoth Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Hoth Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Hoth Therapeutics are expected to grow in the coming year, from ($1.36) to ($0.97) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hoth Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hoth Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Hoth Therapeutics has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.53% of the float of Hoth Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Hoth Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hoth Therapeutics has recently decreased by 48.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Hoth Therapeutics does not currently pay a dividend.

Dividend Growth

Hoth Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.53% of the float of Hoth Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Hoth Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hoth Therapeutics has recently decreased by 48.25%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.93

News Sentiment

Hoth Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Hoth Therapeutics this week, compared to 2 articles on an average week.

Search Interest

6 people have searched for HOTH on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Hoth Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hoth Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.92% of the stock of Hoth Therapeutics is held by insiders.

Percentage Held by Institutions

Only 7.08% of the stock of Hoth Therapeutics is held by institutions.

HOTH Stock Analysis - Frequently Asked Questions

How have HOTH shares performed this year?

Hoth Therapeutics' stock was trading at $0.7481 at the beginning of 2025. Since then, HOTH shares have increased by 92.5% and is now trading at $1.44.

How were Hoth Therapeutics' earnings last quarter?

Hoth Therapeutics, Inc. (NASDAQ:HOTH) posted its quarterly earnings data on Monday, May, 12th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.07.

When did Hoth Therapeutics' stock split?

Hoth Therapeutics shares reverse split on the morning of Wednesday, October 26th 2022.The 1-25 reverse split was announced on Wednesday, October 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Hoth Therapeutics IPO?

Hoth Therapeutics (HOTH) raised $8 million in an initial public offering on Friday, February 15th 2019. The company issued 1,300,000 shares at $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

How do I buy shares of Hoth Therapeutics?

Shares of HOTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hoth Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hoth Therapeutics investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Meta Platforms (META), NVIDIA (NVDA) and Zomedica (ZOM).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:HOTH
• CIK: 1711786
• Web: www.hoththerapeutics.com
• Phone: (646) 756-2997
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Hoth Therapeutics: $4.00
• High Price Target: $5.00
• Low Price Target: $3.00
• Potential Upside/Downside: +177.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -109.18%
• Return on Assets: -100.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.09
• Quick Ratio: 15.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.86 per share
• Price / Book: 1.67

Miscellaneous

• Outstanding Shares: 13,210,000
• Free Float: 12,295,000
• Market Cap: $19.02 million
• Optionable: Not Optionable
• Beta: 0.67